Cargando…
British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy
Currently, there is no guideline to support the use of immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiency disorders in UK. The UK Primary Immunodeficiency Network (UK-PIN) and the British Society of Immunology (BSI) joined forces to address this need. Given the pauci...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585546/ https://www.ncbi.nlm.nih.gov/pubmed/35924867 http://dx.doi.org/10.1093/cei/uxac070 |
_version_ | 1784813516307300352 |
---|---|
author | Grigoriadou, S Clubbe, R Garcez, T Huissoon, A Grosse-Kreul, D Jolles, S Henderson, K Edmonds, J Lowe, D Bethune, C |
author_facet | Grigoriadou, S Clubbe, R Garcez, T Huissoon, A Grosse-Kreul, D Jolles, S Henderson, K Edmonds, J Lowe, D Bethune, C |
author_sort | Grigoriadou, S |
collection | PubMed |
description | Currently, there is no guideline to support the use of immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiency disorders in UK. The UK Primary Immunodeficiency Network (UK-PIN) and the British Society of Immunology (BSI) joined forces to address this need. Given the paucity of evidence, a modified Delphi approach was used covering statements for the initiation, monitoring, discontinuation of IgRT as well as home therapy programme. A group of six consultant immunologists and three nurse specialists created the statements, reviewed responses and feedback and agreed on final recommendations. This guideline includes 22 statements for initiation, 22 statements for monitoring, 11 statement for home therapy, and 19 statements for discontinuation of IgRT. Further areas of research are proposed to improve future delivery of care. |
format | Online Article Text |
id | pubmed-9585546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95855462022-10-24 British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy Grigoriadou, S Clubbe, R Garcez, T Huissoon, A Grosse-Kreul, D Jolles, S Henderson, K Edmonds, J Lowe, D Bethune, C Clin Exp Immunol Editors’ Choice Currently, there is no guideline to support the use of immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiency disorders in UK. The UK Primary Immunodeficiency Network (UK-PIN) and the British Society of Immunology (BSI) joined forces to address this need. Given the paucity of evidence, a modified Delphi approach was used covering statements for the initiation, monitoring, discontinuation of IgRT as well as home therapy programme. A group of six consultant immunologists and three nurse specialists created the statements, reviewed responses and feedback and agreed on final recommendations. This guideline includes 22 statements for initiation, 22 statements for monitoring, 11 statement for home therapy, and 19 statements for discontinuation of IgRT. Further areas of research are proposed to improve future delivery of care. Oxford University Press 2022-08-04 /pmc/articles/PMC9585546/ /pubmed/35924867 http://dx.doi.org/10.1093/cei/uxac070 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Editors’ Choice Grigoriadou, S Clubbe, R Garcez, T Huissoon, A Grosse-Kreul, D Jolles, S Henderson, K Edmonds, J Lowe, D Bethune, C British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy |
title | British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy |
title_full | British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy |
title_fullStr | British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy |
title_full_unstemmed | British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy |
title_short | British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy |
title_sort | british society for immunology and united kingdom primary immunodeficiency network (ukpin) consensus guideline for the management of immunoglobulin replacement therapy |
topic | Editors’ Choice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585546/ https://www.ncbi.nlm.nih.gov/pubmed/35924867 http://dx.doi.org/10.1093/cei/uxac070 |
work_keys_str_mv | AT grigoriadous britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy AT clubber britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy AT garcezt britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy AT huissoona britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy AT grossekreuld britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy AT jolless britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy AT hendersonk britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy AT edmondsj britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy AT lowed britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy AT bethunec britishsocietyforimmunologyandunitedkingdomprimaryimmunodeficiencynetworkukpinconsensusguidelineforthemanagementofimmunoglobulinreplacementtherapy |